Healthpeak Properties, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Healthpeak Properties, Inc. stock analysis DOC overview
Somewhat Bearish -25

Healthpeak Properties Stock: Is DOC Underperforming the Real Estate Sector?

🏢 Healthpeak Properties (DOC) is a healthcare-focused REIT with a $11.9 billion market cap, owning properties like life sciences campuses and senior housing.

⚖️ The company is classified as a large-cap stock ($10B+) and emphasizes disciplined execution to support long-term growth.

📉 DOC stock is currently down 16.9% from its 52-week high of $20.52 reached in March 2025.

🚀 Over the past three months, DOC gained 6.6%, outperforming the Real Estate Select Sector SPDR Fund (XLRE).

📉 However, over the past six months, DOC slumped 7.7% and lagged XLRE’s 3% decline.

📉 Over the past 52 weeks, DOC plunged 16.2%, significantly underperforming XLRE's 3.2% decrease.

📈 The stock trades above its 50-day moving average since mid-February but remains below the 200-day moving average.

💸 Stock declines over the past year are attributed to rising interest rates increasing borrowing costs and reducing investor appetite for REITs.

🧬 Transition toward life sciences properties has introduced leasing and reinvestment risks alongside slower leasing activity.

⚠️ Broader real estate sector weakness and financial pressures among biotech tenants have dampened growth expectations.

🐢 DOC has substantially lagged behind peer Omega Healthcare Investors (OHI), which gained 19.1% over the past year.

📊 Out of 18 analysts covering the stock, the consensus rating is a "Moderate Buy" with a mean price target of $19.47.

💰 The mean price target of $19.47 indicates a 14.2% upside potential from current levels.

⚡ The article title questions if DOC is underperforming the real estate sector, though recent three-month data shows outperformance.

🛑 Several unrelated headlines about Micron, Delta Airlines, and Iran were included in the text but do not relate to Healthpeak Properties.

Bullish Signals
  • Healthpeak Properties (DOC) has outperformed the Real Estate Select Sector SPDR Fund (XLRE) by gaining 6.6% over the past three months while XLRE rose marginally during the same period.
  • Despite a recent stock decline, the company maintains a market cap of around $11.9 billion and is classified as a large-cap stock with a disciplined execution strategy supporting long-term growth.
  • Among the 18 analysts covering DOC stock, the consensus rating is a 'Moderate Buy' with a mean price target of $19.47, indicating approximately 14.2% upside potential from current levels.
Risk Factors
  • Healthpeak Properties stock has slumped 7.7% over the past six months and plunged 16.2% over the past 52 weeks, significantly underperforming the Real Estate Select Sector SPDR Fund's (XLRE) decline of only 3.2% during the same period.
  • The REIT is currently down by 16.9% from its 52-week high of $20.52 reached in March 2025, indicating sustained investor selling pressure and bearish sentiment.
  • Healthpeak stock has substantially lagged behind competitor Omega Healthcare Investors, Inc.'s (OHI) performance, which recorded a 19.1% surge over the past year compared to DOC's decline.
  • Rising interest rates are weighing heavily on REIT valuations by increasing borrowing costs and reducing investor appetite for income-focused assets.
  • The company's transition toward life sciences properties has introduced leasing and reinvestment risks, particularly with slower leasing activity in key lab campuses.
  • Broader weakness in the real estate sector and financial pressures among biotech tenants are dampening growth expectations for Healthpeak Properties.
Full Analysis
Healthpeak Properties, Inc. (DOC) is a Denver-headquartered real estate investment trust with a market capitalization of approximately $11.9 billion, specializing in healthcare-related properties including life sciences campuses, outpatient medical offices, and senior housing facilities. The article assesses whether the stock is underperforming relative to the broader real estate sector, noting that DOC has traded below its 52-week high of $20.52 touched in March 2025, declining 16.9% from that peak. Despite a recent 6.6% gain over the past three months that outpaced the marginal rise of the Real Estate Select Sector SPDR Fund (XLRE), DOC has struggled more significantly over longer periods; it slipped 7.7% over six months and plummeted 16.2% over the past 52 weeks, compared to XLRE's declines of 3% and 3.2% respectively during those same intervals. Technical analysis indicates that while the stock has remained above its 50-day moving average since mid-February, it is currently trading below the 200-day moving average with ongoing fluctuations. The recent performance decline for Healthpeak Properties is attributed to rising interest rates increasing borrowing costs and dampening investor appetite for income-focused assets, alongside risks introduced by the company's transition toward life sciences properties. Specific industry challenges include slower leasing activity in key lab campuses, broader weakness within the real estate sector, and financial pressures affecting biotech tenants, which have collectively reduced growth expectations. The stock also lags behind competitor Omega Healthcare Investors, Inc. (OHI), which posted 7.9% gains over six months and a 19.1% surge over the past year, contrasting sharply with DOC's underperformance. Of the 18 analysts covering DOC, consensus ratings stand as a "Moderate Buy" with a mean price target of $19.47, suggesting a potential 14.2% upside from current price levels. The report concludes that while Healthpeak continues to emphasize disciplined execution and a focused approach to support its long-term growth vision, the company faces an environment where it is currently trailing both sector benchmarks and key peers like OHI.